Tirzepatide shot vlogs: what the science says about GLP-1 journeys

What did @allpowerfulnerd actually say?

This video is not a medical tutorial. It is a personal moment. The creator is documenting their fourth tirzepatide injection while reciting what sounds like spoken word or song lyrics about surviving suicidal ideation and loss. The phrase "even when you wanna die" sits alongside the Mounjaro hashtag, which makes this one of the more emotionally raw GLP-1 diary posts currently circulating on TikTok.

There are zero dosing instructions, zero product comparisons, and zero health claims made in the literal transcript. The creator is not telling viewers to take anything. They are sharing a moment. That distinction matters a lot when we are talking about regulated medications on a public platform with nearly 49,000 views.

Does the science back this up?

There is nothing in the transcript to fact-check medically in the traditional sense. However, the pairing of mental health themes with GLP-1 use is actually worth examining, because the science here is genuinely complicated and often misrepresented elsewhere on the platform.

Tirzepatide, the active ingredient in Mounjaro and Zepbound, targets both GIP and GLP-1 receptors. Early data suggests GLP-1 receptor agonists may have mood-related effects. A 2023 analysis published in Diabetes Care (Rubino et al.) found no increased suicide risk with semaglutide, but the FDA still added a monitoring notice in 2023 following reports. Separately, a 2024 study in Nature Medicine (Blüher et al.) suggested GLP-1 receptor agonists may reduce reward-seeking behavior, which could interact with mood in complex ways. The research is preliminary. Anyone using these medications while managing mental health conditions should be doing so with clinical oversight, full stop.

What did they get wrong (or right)?

The creator did not get anything medically wrong, because they did not make medical claims. That is worth saying plainly. Too many GLP-1 videos on TikTok are full of confident dosing advice, compound pharmacy recommendations, and before-and-after framing that borders on advertising. This video is none of those things.

What the creator got right, implicitly, is showing that GLP-1 use does not exist in a vacuum. People starting these medications often have layered histories with their bodies, with food, and with mental health. The hashtag pairing of mentalhealthmatters and glp1 is not accidental. Research supports this complexity. Obesity is associated with elevated rates of depression and anxiety (Luppino et al., 2010, Archives of General Psychiatry), and starting a medication that changes appetite and body image can surface difficult emotions. The video does not explain any of this, but it embodies it.

What should you actually know?

If you are on tirzepatide or semaglutide and also managing depression, suicidal ideation, or grief, your prescribing clinician needs to know. This is not alarmism. The FDA's 2023 safety communication on GLP-1 medications and neuropsychiatric symptoms was precautionary, and subsequent data has been somewhat reassuring, but "somewhat reassuring" is not the same as "no concern."

The creator's lyrics reference loving someone whose "life was too short," suggesting grief may be part of the context here. Bereavement during active medication titration is clinically relevant. GLP-1 medications are titrated over weeks, and the period of dose escalation can come with nausea, fatigue, and mood fluctuations that compound emotional distress. If you recognize yourself in this video, please tell your provider what is actually going on in your life, not just what the scale says.

• The FDA added a monitoring note for GLP-1 medications and suicidal ideation in 2023, though causality has not been established.
• Clinical guidelines recommend baseline mental health screening before initiating GLP-1 therapy in patients with psychiatric history.
• Crisis resources: 988 Suicide and Crisis Lifeline (call or text 988 in the US).